Nexstim Plc: Composition of the Shareholders’ Nomination Committee

Company Announcement, Helsinki, 24 October 2023 at 3 PM (EEST)


Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the composition of the Shareholders’ Nomination Committee.

Leena Niemistö, Chair of the Board of Nexstim and representative of the Company’s largest shareholder, continues to chair the Nomination Committee. Ossi Haapaniemi, and Kyösti Kakkonen as a representative of Joensuun Kauppa ja Kone Oy continue as members of the committee.

According to the document establishing Nexstim’s Nomination Committee, it must have three to four members. The three largest shareholders of the Company each nominate one member; if a shareholder does not exercise the right to nominate a representative, the right is passed on to the next largest shareholder.

The Nomination Committee will start its work during 2023.


Further information is available on the website, or by contacting:

Leena Niemistö, Chair of Board of Directors
+358 9 2727 170

The Company’s Certified Advisor is Erik Penser Bank. 

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit